Cardiac Troponin T in Tofersen-Treated SOD1 ALS Patients: Beginning to Resolve the Catch-22 of Identifying Treatment Responsive Biomarkers in ALS Drug Development

Authors

James D. Berry, Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital, Boston, Massachusetts, USA.
Robert Bowser, Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.

Document Type

Editorial

Keywords

ALS, SOD1, amyotrophic lateral sclerosis, biomarker, tofersen

Publication Date

11-1-2025

Publication Title

Muscle & nerve

E-ISSN

1097-4598

Volume

72

Issue

5

First Page

1039

Last Page

1041

PubMed ID

40884436

Digital Object Identifier (DOI)

10.1002/mus.70017

Recommended Citation

Berry, James D. and Bowser, Robert, "Cardiac Troponin T in Tofersen-Treated SOD1 ALS Patients: Beginning to Resolve the Catch-22 of Identifying Treatment Responsive Biomarkers in ALS Drug Development" (2025). Translational Neuroscience. 2455.
https://scholar.barrowneuro.org/neurobiology/2455